ALPACA (J3L-MC-EZEB) (Follow-up) LY3473329 Lp(a) siRNA (subcutane) for secondary MACE prevention in patients with elevated Lp(a) Medicine LY3819469 Lp(a) siRNA (subcutaan) Population ASCVD Phase II Starting year 2022 Director of Study dr. M.F.L. Meijs (Cardioloog) Enschede, Medisch Spectrum Twente
